XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
US Stock MarketDetailed Quotes
GSK GlaxoSmithKline
- 36.170
- -0.380-1.04%
Close Feb 14 16:00 ET
- 36.210
- +0.040+0.11%
Post 20:01 ET
73.82BMarket Cap23.14P/E (TTM)
36.605High36.160Low4.54MVolume36.480Open36.550Pre Close165.04MTurnover0.23%Turnover Ratio23.14P/E (Static)2.04BShares44.86352wk High4.30P/B71.35BFloat Cap31.71552wk Low1.52Dividend TTM1.97BShs Float44.863Historical High4.21%Div YieldTTM1.22%Amplitude6.376Historical Low36.337Avg Price1Lot Size
GlaxoSmithKline Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 3.46%31.38B | 0.81%8.12B | -1.66%8.01B | 9.84%7.88B | 5.93%7.36B | 3.42%30.33B | 9.16%8.05B | 4.06%8.15B | 3.59%7.18B | -3.32%6.95B |
| Operating revenue | 3.46%31.38B | 0.81%8.12B | -1.66%8.01B | 9.84%7.88B | 5.93%7.36B | 3.42%30.33B | 9.16%8.05B | 4.06%8.15B | 3.59%7.18B | -3.32%6.95B |
| Cost of revenue | 5.64%9.05B | 5.83%2.56B | 5.50%2.4B | 9.83%2.12B | 1.39%1.97B | -10.35%8.57B | 8.04%2.42B | -6.23%2.27B | -11.21%1.93B | -28.49%1.94B |
| Gross profit | 2.60%22.33B | -1.35%5.56B | -4.43%5.62B | 9.84%5.76B | 7.69%5.39B | 10.08%21.76B | 9.65%5.63B | 8.68%5.88B | 10.37%5.25B | 11.96%5.01B |
| Operating expense | 26.97%18.31B | 8.99%4.86B | 38.21%5.43B | 32.56%4.12B | 33.39%3.9B | 10.56%14.42B | 50.00%4.46B | -6.86%3.93B | -15.44%3.11B | 34.22%2.93B |
| Selling and administrative expenses | 17.37%11.02B | -0.56%2.66B | 65.51%3.8B | 8.69%2.47B | -2.61%2.09B | 12.10%9.39B | 9.84%2.68B | 11.67%2.3B | 9.78%2.27B | 18.27%2.14B |
| -General and administrative expense | 17.37%11.02B | -0.56%2.66B | 65.51%3.8B | 8.69%2.47B | -2.61%2.09B | 12.10%9.39B | 9.84%2.68B | 11.67%2.3B | 9.78%2.27B | 18.27%2.14B |
| Research and development costs | 2.86%6.4B | -0.78%2.03B | -7.37%1.46B | 10.14%1.48B | 13.81%1.43B | 13.39%6.22B | 13.91%2.05B | 17.01%1.58B | 7.97%1.34B | 14.23%1.26B |
| Other operating expenses | --1.53B | --344M | -8.72%335M | --318M | --533M | ---- | ---- | -65.64%367M | ---- | ---- |
| Operating profit | -45.26%4.02B | -40.66%696M | -90.30%189M | -23.12%1.65B | -28.43%1.49B | 9.15%7.35B | -45.79%1.17B | 63.64%1.95B | 98.06%2.14B | -9.20%2.08B |
| Net non-operating interest income expense | 25.58%-547M | 44.62%-139M | 21.52%-124M | 1.32%-150M | 22.99%-134M | 11.02%-735M | 5.99%-251M | 11.24%-158M | 16.94%-152M | 12.12%-174M |
| Non-operating interest income | 154.17%122M | 189.47%34M | 33.33%32M | -27.27%24M | 10.34%32M | 54.84%48M | -100.00%-38M | 9.09%24M | 57.14%33M | 314.29%29M |
| Non-operating interest expense | -7.72%669M | 11.61%173M | -14.29%156M | -5.95%174M | -18.23%166M | -12.23%725M | -28.57%155M | -9.00%182M | -9.31%185M | -0.98%203M |
| Total other finance cost | ---- | ---- | ---- | ---- | ---- | 87.10%58M | ---- | ---- | ---- | ---- |
| Other net income (expense) | ||||||||||
| Special income (charges) | 100.85%6M | 100.85%6M | --0 | --0 | --0 | 42.81%-704M | 42.73%-705M | --0 | --0 | --1M |
| -Less：Restructuring and merger&acquisition | ---- | ---- | ---- | ---- | ---- | -50.78%791M | ---- | ---- | ---- | ---- |
| -Less:Other special charges | 93.10%-6M | 93.02%-6M | ---- | ---- | ---- | 76.86%-87M | ---86M | ---- | ---- | ---1M |
| Income before tax | -42.66%3.48B | 48.55%563M | -96.43%64M | -24.76%1.5B | -28.95%1.36B | 7.75%6.06B | -76.69%379M | 76.98%1.79B | 121.76%1.99B | -8.93%1.91B |
| Income tax | -30.42%526M | 426.32%62M | -100.39%-1M | -21.07%191M | -0.72%274M | 6.93%756M | -2,000.00%-19M | 10.30%257M | 61.33%242M | -14.55%276M |
| Net income | -44.40%2.95B | 25.88%501M | -95.76%65M | -25.27%1.3B | -33.72%1.08B | -66.02%5.31B | -75.43%398M | -85.87%1.53B | 78.97%1.75B | -24.73%1.63B |
| Net income continuous Operations | -44.40%2.95B | 25.88%501M | -95.76%65M | -25.27%1.3B | -33.72%1.08B | 7.86%5.31B | -75.51%398M | 96.92%1.53B | 133.91%1.75B | -7.91%1.63B |
| Net income discontinuous operations | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Minority interest income | -1.05%376M | 81.25%87M | 75.71%123M | 8.26%131M | -75.18%35M | -42.86%380M | -61.60%48M | 84.21%70M | -11.68%121M | -61.37%141M |
| Net income attributable to the parent company | -47.75%2.58B | 18.29%414M | -103.96%-58M | -27.77%1.17B | -29.80%1.05B | -67.05%4.93B | -76.59%350M | -86.47%1.46B | 93.79%1.62B | -17.31%1.49B |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | -47.75%2.58B | 18.29%414M | -103.96%-58M | -27.77%1.17B | -29.80%1.05B | -67.05%4.93B | -76.59%350M | -86.47%1.46B | 93.79%1.62B | -17.31%1.49B |
| Basic earnings per share | -48.03%1.264 | 17.44%0.202 | -103.88%-0.028 | -28.18%0.576 | -30.16%0.514 | -67.26%2.432 | -76.82%0.172 | -86.55%0.722 | 140.99%0.802 | -18.04%0.736 |
| Diluted earnings per share | -48.12%1.244 | 17.65%0.2 | -103.93%-0.028 | -28.21%0.57 | -30.41%0.508 | -67.26%2.398 | -76.71%0.17 | -86.55%0.712 | 140.90%0.794 | -17.79%0.73 |
| Dividend per share | 8.15%1.217 | 5.45%0.296 | 10.70%0.2992 | 3.82%0.3019 | 12.82%0.3198 | -25.33%1.1253 | 0.16%0.2807 | -14.72%0.2703 | -15.84%0.2908 | -49.75%0.2835 |
| Currency Unit | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Trending Stocks
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio?
Moo Live
Jan 30 03:25
FOMC Press Conference, January 29, 2025